Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography
Open Access
- 1 April 2019
- journal article
- research article
- Published by Wiley in Cardiology Research and Practice
- Vol. 2019, 1-7
Abstract
Background. Residual angina after PCI is a frequently occurring disease. Ivabradine improves symptoms but its role in patients without left ventricular systolic dysfunction is still unclear. The aim was to quantify the effects of ivabradine in terms of MVO2 indicators and diastolic function. Methods. Twenty-eight consecutive patients with residual angina after PCI were randomized to ivabradine 5 mg twice/day (IG) or standard therapy (CG). All patients performed a stress echocardiography at the enrollment and after 30 days. MVO2 was estimated from double product (DP) and triple product (TP) integrating DP with ejection time (ET). Diastolic function was evaluated determining E and A waves, E′ measurements, and E/E′ ratio both at rest and at the peak of exercise. Results. The exercise time was longer in IG 9′49″ ± 48″ vs 8′09″ ± 59″ in CG (), reaching a greater workload (IG 139.3 ± 13.4 vs CG 118.7 ± 19.6 Watts; ). MVO2 expressed with DP and TP was significantly higher in IG (DP: IG 24194 ± 2697 vs CG 20358 ± 4671.8, ; TP: IG 17239 ± 4710 vs CG 12206 ± 4413, ). At peak exercise, the ET was diminished in IG than CG. The analysis of diastolic function after the exercise revealed an increase of E and A waves, without difference in the E/A ratio. The E′ wave was higher in IG than CG, and in the same group, the differences between baseline and peak exercise were greater (∆E′3.14 ± 0.7 vs 2.4 ± 1.13, ). The E/E′ ratio was reduced in patients treated with ivabradine (IG 10.2 ± 2.0 vs CG 7.9 ± 1.6, ). Conclusions. Ivabradine seems to produce a significant improvement of ischemic threshold, chronotropic reserve, and diastolic function.
Keywords
This publication has 25 references indexed in Scilit:
- Comparison of Effects of Ivabradine versus Carvedilol in Murine Model with the Coxsackievirus B3-Induced Viral MyocarditisPLOS ONE, 2012
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyEuropean Heart Journal, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reductionBritish Journal of Pharmacology, 2008
- Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E–Deficient MiceCirculation, 2008
- Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reductionEuropean Heart Journal, 2008
- Bradycardia Induces Angiogenesis, Increases Coronary Reserve, and Preserves Function of the Postinfarcted HeartCirculation, 2004
- The Properties of the Pacemaker Current IFin Human Ventricular Myocytes are Modulated by Cardiac DiseaseJournal of Molecular and Cellular Cardiology, 2001
- Systolic Time Intervals in Heart Failure in ManCirculation, 1968
- Relationships between left ventricular ejection time, stroke volume, and heart rate in normal individuals and patients with cardiovascular diseaseAmerican Heart Journal, 1961